Sofia Heigis, MSc

Chief Executive Officer, CEO

Sofia was appointed Chief Executive Officer in August 2023.

Sofia joined Oncopeptides in August 2020 as Senior Vice President and Global Head Medical Affairs. She was appointed Chief Commercial Officer and Managing Director Germany in 2022. Sofia was engaged in the preparedness and launch of Pepaxto in the US, and has led the preparations of the commercialization of Pepaxti in Europe. She has been a member of the Leadership Team since November 2021.

Sofia brings broad experience from leading international roles in Medical Affairs, Regulatory Affairs, Market Ethics, Pharmacovigilance, Real World Evidence as well as several Marketing and Sales roles at Astra Zeneca, and has been engaged in both global and local product launches.

Sofia holds a Master of Pharmacology from the University of Gothenburg, including a Master Thesis in Pharmacology from Bond University. She has an Executive Master in Strategy, and is a member of the business network for female leaders, Ruter Dam.

Born: 1980

Holdings in Oncopeptides: 86,908 shares, 1,776,502 share awards* and 123,561 options*.

Other current positions: –

Eva Nordström, MSc Pharm

Chief Operating Officer (COO) and Deputy Managing Director

Eva Nordström was appointed as Head of Clinical Development in 2012, Chief Operating Officer 2020 and Deputy Managing Director 2021. Eva is responsible for strategic and operational deliveries in Biometrics, CMC, Clinical Operations, Global Drug Supply and Preclinical Operations.

Previous positions Eva has held include Global Product Director and Vice President roles at Pharmacia and AstraZeneca based both in Sweden and the USA. She has led international cross-functional teams through all phases of drug development, including phase III and product launches. Eva has been responsible for individual project strategies including their implementation as well as disease area strategies, portfolio management and in-licensing.

Eva holds an MSc Pharm from Uppsala University and an Executive MBA from Stockholm School of Economics.

Born: 1970

Holdings in Oncopeptides: 280,464 shares, 316,295 share awards* and 363,665 options*.

Other current positions: Board member of Oxcia AB, Alternate Director of Utilica AB.

Henrik Bergentoft, MSc

Chief Financial Officer (CFO)

Henrik was appointed CFO in 2023 and is responsible for Finance, Legal, IT and administration.

Henrik brings broad experience from  several CFO-positions in listed companies; RaySearch Laboratories, C-RAD, MSAB, Nordkom, Aerocrine and Contextvision. He started his career as auditor with Andersen/Deloitte.

Education: Henrik has a Master of science in Business Administration from the University of Uppsala.

Born: 1974

Holdings in Oncopeptides: 23,332 shares and 79,728 share awards*.

Other current positions: –

David Augustsson

Director of IR and Communications

David Augustsson joined Oncopeptides in 2023 as Head of the company’s investor relations, communications and corporate brand.

David has a broad experience from leading communication roles in international and listed companies. Between 2016 and 2023, he worked for global financial services company Nasdaq, where he led the communications teams for the company’s European operations as well as its global technology business. He has also worked as a consultant at a number of agencies, including Prime WeberShandwick and Hill+Knowlton, where he primarily has worked with financial communications and issues management. David is also a regular guest lecturer within strategic communication and issues management at Berghs School of Communication in Stockholm.

David holds a Master’s degree in International Economics and Management from Uppsala University and Wirtschaftsuniversität Vienna
.

Born: 1984

Holdings in Oncopeptides: 16,332 shares and 60,483 share awards*

Other current positions: –

Lotta Larsson

Head of Human Resources

Lotta joined Oncopeptides in September 2024 as Head of Human Resources.

Lotta brings almost 20 years of HR leadership experience from the life sciences sector, with deep expertise in establishing and managing global HR functions in fast-growing, international environments. Her focus has been on aligning HR strategies with business objectives to drive long-term growth and efficiency and delivering high-quality HR support across the full range of HR activities. Prior to joining Oncopeptides, Lotta held senior HR roles at medtech company RaySearch Laboratories AB and biotech company BioLamina AB.

Lotta holds a Bachelor of Applied Science (B.A.Sc.) in Dietetics and Clinical Nutrition Services and a Bachelor of Applied Science (B.A.Sc.) in Health Sciences Health Promotion from Deakin University, Australia.

Born: 1977

Holdings in Oncopeptides: –

Other current positions: –

Stefan Norin, MD, PhD

Chief Medical Officer (CMO)

Stefan was appointed as Chief Medical Officer in September 2023.

Stefan joined Oncopeptides in March 2019, as Clinical Study Physician, appointed Global Clinical Lead in 2020, Head of Clinical Development in 2022 and Head of Clinical Science in 2023.

In his role, he is responsible for Research & Development and Pharmacovigilance.

Stefan has a background as a specialist in Internal Medicine and Hematology and has 20 years of clinical experience. He has a PhD from Karolinska Institute.

Previous roles include Associate Director, Clinical R&D at Medivir AB and Head of Lymphoma Division, Department of Hematology at Karolinska University Hospital.

Born: 1972

Holdings in Oncopeptides: 9,664 shares, 126,456 share awards* and 14,957 options*.

Other current positions: –

Jakob Lindberg, Med Lic

Senior Scientific Advisor to the Leadership Team

Jakob Lindberg was the CEO of Oncopeptides from 2011 until June 2020, as well as from November 2021 until January 2023. During July 2020 until November 2021 and between January 2023 and May 2024 he was the Chief Scientific Officer of Oncopeptides. Previous roles include being an analyst at Merrill Lynch & Co and a consultant at McKinsey & Co. Jakob was co-founder of Cellectricon, a provider of cell-based screening services to accelerate drug discovery, where he has also served as CEO.

Jakob has studied medicine at the Karolinska Institute. He gained a Med Lic in Molecular Immunology and a MSc in pre-clinical medicine. He also has a BA in Finance and Administration from the Stockholm University.